GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Forward Dividend Yield %

AIM ImmunoTech (STU:HXB2) Forward Dividend Yield % : 0.00% (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Forward Dividend Yield %?

As of today (2024-05-25), the Forward Annual Dividend Yield of AIM ImmunoTech is 0.00%.

As of today (2024-05-25), the Trailing Annual Dividend Yield of AIM ImmunoTech is 0.00%.

STU:HXB2's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

AIM ImmunoTech's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of AIM ImmunoTech's Forward Dividend Yield %

For the Biotechnology subindustry, AIM ImmunoTech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Forward Dividend Yield % falls into.



AIM ImmunoTech Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


AIM ImmunoTech  (STU:HXB2) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


AIM ImmunoTech Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines